Kamada Company Profile (NASDAQ:KMDA)

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMDA
  • CUSIP: N/A
  • Web: www.kamada.com
Capitalization:
  • Market Cap: $207.75 million
  • Outstanding Shares: 36,154,000
Average Prices:
  • 50 Day Moving Avg: $6.71
  • 200 Day Moving Avg: $6.78
  • 52 Week Range: $3.85 - $8.61
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 17.50
  • P/E Growth: 16.11
Sales & Book Value:
  • Annual Revenue: $74.35 million
  • Price / Sales: 2.72
  • Book Value: $1.75 per share
  • Price / Book: 3.20
Profitability:
  • EBIDTA: ($3,660,000.00)
  • Net Margins: -11.31%
  • Return on Equity: -12.55%
  • Return on Assets: -8.72%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 2.82%
  • Quick Ratio: 1.71%
Misc:
  • Average Volume: 66,694 shs.
  • Beta: 1.09
  • Short Ratio: 1.47
 

Frequently Asked Questions for Kamada (NASDAQ:KMDA)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Tuesday, May, 16th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.08. The business earned $11.65 million during the quarter, compared to analysts' expectations of $20.82 million. Kamada had a negative return on equity of 12.55% and a negative net margin of 11.31%. View Kamada's Earnings History.

Where is Kamada's stock going? Where will Kamada's stock price be in 2017?

2 brokerages have issued 1 year price objectives for Kamada's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Kamada's stock price to reach $9.50 in the next twelve months. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:

  • Leon Yehuda Recanati, Chairman of the Board
  • Amir London, Chief Executive Officer
  • Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
  • David Tsur, Deputy Chairman of the Board
  • Ruth Wolfson, Senior Vice President - Scientific Affairs
  • Barak Bashari, Vice President - Operations
  • Shani Dotan, Vice President - Human Resources
  • Yael Brenner, Vice President - Quality
  • Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
  • Eran Schenker, Vice President - Medical Director

How do I buy Kamada stock?

Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of Kamada stock can currently be purchased for approximately $5.60.


MarketBeat Community Rating for Kamada (NASDAQ KMDA)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kamada (NASDAQ:KMDA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (69.64% upside)

Analysts' Ratings History for Kamada (NASDAQ:KMDA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017Jefferies Group LLCReiterated RatingBuy$9.00HighView Rating Details
2/7/2017HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Kamada (NASDAQ:KMDA)
Earnings by Quarter for Kamada (NASDAQ:KMDA)
Earnings History by Quarter for Kamada (NASDAQ KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kamada (NASDAQ:KMDA)
2017 EPS Consensus Estimate: $0.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.00$0.00$0.00
Q2 20171$0.10$0.10$0.10
Q3 20171$0.03$0.03$0.03
Q4 20171$0.06$0.06$0.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Kamada (NASDAQ:KMDA)
Latest Headlines for Kamada (NASDAQ:KMDA)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Kamada Ltd. : July 7, 2017
finance.yahoo.com - July 8 at 12:04 PM
americanbankingnews.com logo$32.90 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This Quarter
www.americanbankingnews.com - July 6 at 10:08 AM
americanbankingnews.com logoZacks: Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Earnings of $0.12 Per Share
www.americanbankingnews.com - July 4 at 6:24 PM
finance.yahoo.com logoKamada Withdraws Inhaled AAT Marketing Application in EU
finance.yahoo.com - June 23 at 6:35 PM
streetinsider.com logoKamada (KMDA) Withdrawal of European MAA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
www.streetinsider.com - June 23 at 7:34 AM
nasdaq.com logoKamada Ltd. (KMDA) Is Sinking After European Application Withdrawn
www.nasdaq.com - June 23 at 7:34 AM
rttnews.com logoKamada Ltd. (KMDA) Sank To Nearly A 5-Month Low
www.rttnews.com - June 23 at 7:34 AM
finance.yahoo.com logoKamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
finance.yahoo.com - June 22 at 12:44 PM
finance.yahoo.com logoETFs with exposure to Kamada Ltd. : June 16, 2017
finance.yahoo.com - June 16 at 7:04 PM
finance.yahoo.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 10:58 AM
streetinsider.com logoKamada (KMDA) Receives Additional Milestone Payment Under GLASSIA Agreement with Shire
www.streetinsider.com - June 13 at 8:36 AM
finance.yahoo.com logoKamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire
finance.yahoo.com - June 12 at 3:21 PM
americanbankingnews.com logo$32.90 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 10 at 8:22 AM
americanbankingnews.com logo$0.12 Earnings Per Share Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 8 at 4:30 PM
finance.yahoo.com logoKamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
finance.yahoo.com - June 7 at 9:39 AM
finance.yahoo.com logoKamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
finance.yahoo.com - June 5 at 9:58 AM
finance.yahoo.com logoKamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
finance.yahoo.com - May 24 at 11:14 AM
americanbankingnews.com logoKamada Ltd (KMDA) to Post Q2 2017 Earnings of $0.10 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 19 at 7:16 AM
americanbankingnews.com logoShort Interest in Kamada Ltd (KMDA) Decreases By 9.0%
www.americanbankingnews.com - May 18 at 4:22 PM
americanbankingnews.com logoKamada Ltd (KMDA) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 12:30 PM
americanbankingnews.com logoFY2017 EPS Estimates for Kamada Ltd Reduced by Jefferies Group (KMDA)
www.americanbankingnews.com - May 18 at 10:38 AM
finance.yahoo.com logoKamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 17 at 6:10 PM
americanbankingnews.com logoKamada Ltd (KMDA) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - May 17 at 11:34 AM
americanbankingnews.com logoKamada Ltd (KMDA) Issues Earnings Results
www.americanbankingnews.com - May 17 at 10:03 AM
finance.yahoo.com logoKamada Reports 2017 First Quarter Financial Results
finance.yahoo.com - May 16 at 10:49 AM
finance.yahoo.com logoKamada reports 1Q loss
finance.yahoo.com - May 16 at 10:49 AM
finance.yahoo.com logoInvestor Network: Kamada Ltd to Host Earnings Call
finance.yahoo.com - May 16 at 10:49 AM
americanbankingnews.com logo Analysts Anticipate Kamada Ltd (KMDA) Will Post Quarterly Sales of $20.82 Million
www.americanbankingnews.com - May 14 at 9:24 AM
finance.yahoo.com logoKamada to Host First Quarter 2017 Financial Results Conference Call on May 16
finance.yahoo.com - May 8 at 9:26 AM
americanbankingnews.com logoKamada (KMDA) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:00 AM
americanbankingnews.com logoKamada (KMDA) Receiving Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 12:14 AM
americanbankingnews.com logoKamada (KMDA) Receives Media Impact Score of -0.12
www.americanbankingnews.com - April 24 at 1:38 PM
americanbankingnews.com logoKamada Ltd (KMDA) Expected to Announce Quarterly Sales of $20.82 Million
www.americanbankingnews.com - April 23 at 8:16 AM
americanbankingnews.com logoKamada (KMDA) Receiving Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 5:28 PM
americanbankingnews.com logoKamada (KMDA) Earns Media Impact Score of 0.40
www.americanbankingnews.com - April 13 at 3:16 PM
americanbankingnews.com logoKamada's (KMDA) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:53 PM
finance.yahoo.com logoKAMADA LTD Financials
finance.yahoo.com - March 7 at 5:56 PM
finance.yahoo.com logoKamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)
finance.yahoo.com - March 2 at 6:24 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver ... - StreetInsider.com
www.streetinsider.com - February 22 at 6:22 PM
streetinsider.com logoKamada (KMDA) to Collaborate with MGH on Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
www.streetinsider.com - February 22 at 12:25 PM
us.rd.yahoo.com logoKamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation
us.rd.yahoo.com - February 22 at 12:25 PM
us.rd.yahoo.com logo6:33 am Kamada announces a collaboration w/ Massachusetts General Hospital to conduct a study evaluating the potential benefit of its Liquid Alpha-1 Antitrypsin on liver preservation
us.rd.yahoo.com - February 22 at 12:25 PM
finance.yahoo.com logoKamada Announces Appointment of Biopharmaceutical Industry Veteran, Gwen Melincoff, to its Board of Directors
finance.yahoo.com - February 8 at 6:56 PM
globenewswire.com logoKamada Reports Financial Results for the Fourth Quarter and Full-Year 2016
globenewswire.com - February 6 at 10:21 AM
finance.yahoo.com logoKamada to Host Fiscal Year 2016 Financial Results Conference Call on February 6
finance.yahoo.com - February 1 at 6:58 PM
globenewswire.com logoKamada Announces Positive Scientific Advice Response from the European ...
globenewswire.com - January 23 at 10:37 AM
streetinsider.com logoKamada (KMDA) Announces Positive Scientific Advice Response from CHMP on G1-AAT IV for aGvHD
www.streetinsider.com - January 23 at 10:37 AM
finance.yahoo.com logo6:30 am Kamada announces positive scientific advice response from the EMA focused on Alpha-1 Antitrypsin IV for treatment of acute graft-versus-host disease; co is in the process of reviewing CHMP guidance
finance.yahoo.com - January 23 at 10:37 AM
finance.yahoo.com logoKamada Announces Positive Scientific Advice Response from the European Medicines Agency Focused on Alpha-1 Antitrypsin IV for Treatment of Acute Graft-Versus-Host Disease
finance.yahoo.com - January 23 at 10:37 AM
streetinsider.com logoKamada (KMDA) Enters Recombinant Human Alpha 1 Antitrypsin Development Agreement
www.streetinsider.com - November 15 at 6:25 PM

Social

Chart

Kamada (KMDA) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff